生物制药公司Vericel Corporation（VCEL）今日盘中股价大跌13.98%，引发市场关注。这一显著下跌主要源于公司最新发布的季度财报未能达到分析师预期。
根据公司公布的截至6月30日的季度业绩报告，Vericel调整后每股亏损1美分，虽然高于去年同期的每股亏损10美分，但未能达到分析师平均预期的每股亏损3美分。公司季度营收为6324万美元，同比增长20.1%，但仍低于分析师预期的6449万美元。此外，公司报告的季度净亏损为55.3万美元。
尽管Vericel的业绩有所改善，但未能达到市场预期，这可能是导致投资者信心下降的主要原因。值得注意的是，分析师对该公司的评级仍然保持积极，平均评级为"强力买入"，12个月目标价中位数为58.50美元，较前一交易日收盘价高出约30.5%。然而，公司股价今年迄今已下跌26.0%，显示出市场对其表现的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.